FDA Approves Takeda-Protagonist Drug for Rare Blood Cancer
PTGX has more than doubled off its 52-week low of $54.5.
Summary
The FDA approved the first-of-its-kind drug from Takeda and Protagonist Therapeutics for a rare blood cancer. This is a major regulatory milestone that validates the drug's efficacy and safety, opening a new revenue stream for Protagonist. The approval follows the company's Q1 2026 profitability, which was partly driven by a $50 million milestone for ICOTYDE's FDA approval, indicating a pattern of successful regulatory outcomes. The drug's market potential in rare blood cancer is significant, and this approval could lead to near-term commercialization and partnership revenues. Investors should watch for launch details and pricing, as well as any additional milestone payments from Takeda.
At the time of this announcement, PTGX was trading at $147.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $54.50 to $160.81. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.